Table I.
Patient and disease characteristics.
| Duration of ADT, months | |||
|---|---|---|---|
| Parameter | <36 (n=54) | ≥36 (n=119) | P-value |
| Age, years | |||
| Median (range) | 74 (83–58) | 74 (87–56) | 0.73 |
| T stage, n (%) | |||
| T1 | 12 (22) | 18 (15) | |
| T2 | 9 (17) | 20 (17) | |
| T3 | 31 (57) | 74 (62) | |
| T4 | 2 (4) | 7 (6) | 0.67 |
| Gleason score, n (%) | |||
| ≤6 | 6 (11) | 11 (9) | |
| 7 | 14 (26) | 38 (32) | |
| ≥8 | 34 (63) | 70 (59) | 0.71 |
| PSA levela, n (%) | |||
| <10.0 | 15 (28) | 20 (17) | |
| 10.0–20.0 | 7 (13) | 27 (23) | |
| ≥20.0 | 32 (59) | 72 (60) | 0.14 |
| Irradiated site, n (%) | |||
| Prostate only | 3 (6) | 14 (12) | |
| Pelvic lymph node and prostate | 51 (94) | 105 (88) | 0.28 |
a
PSA is represented as ng/ml. ADT, androgen deprivation therapy; PSA, prostate-specific antigen.